Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

Phase 1

Terminated

Conditions: Atopic Dermatitis
Healthy

Interventions: Drug: LY3872386
Drug: Placebo
Drug: Prednisone

First Posted Date: 2023-11-07

Last Posted Date: 2024-07-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 18

Registration Number: NCT06119529

Locations: 🇺🇸
CenExel ACT, Anaheim, California, United States
🇺🇸
Fortrea Clinical Research Unit, Daytona Beach, Florida, United States

A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3537982
Drug: Digoxin
Drug: Midazolam
Drug: Rosuvastatin

First Posted Date: 2023-11-01

Last Posted Date: 2024-11-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 35

Registration Number: NCT06111521

Locations: 🇺🇸
ICON Early Clinical & Bioanalytical Solutions, Salt Lake City, Utah, United States

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Phase 3

Recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Orforglipron
Drug: Placebo

First Posted Date: 2023-10-31

Last Posted Date: 2024-12-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 520

Registration Number: NCT06109311

Locations: 🇧🇷
Quanta Diagnóstico e Terapia, Curitiba, Paraná, Brazil
🇧🇷
CEDOES, Vitória, Espírito Santo, Brazil
🇺🇸
MD First Research - Chandler, Chandler, Arizona, United States

and more 67 locations

A Study of [14C]-LOXO-783 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [¹⁴C]-LOXO-783
Drug: LOXO-783

First Posted Date: 2023-10-26

Last Posted Date: 2024-07-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT06102512

Locations: 🇺🇸
Fortrea Clinical Research, Madison, Wisconsin, United States

A Phase I Study of LY3502970 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3502970
Drug: [14C]-LY3502970

First Posted Date: 2023-10-17

Last Posted Date: 2024-03-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 10

Registration Number: NCT06085482

Locations: 🇺🇸
Covance Clinical Research Inc, Madison, Wisconsin, United States

A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Phase 2

Recruiting

Conditions: Diabetic Peripheral Neuropathy

Interventions: Drug: LY3556050
Drug: Placebo

First Posted Date: 2023-10-10

Last Posted Date: 2024-12-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 410

Registration Number: NCT06074562

Locations: 🇺🇸
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States
🇺🇸
Headlands Research - Scottsdale, Scottsdale, Arizona, United States
🇺🇸
Orange Grove Family Practice, Tucson, Arizona, United States

and more 66 locations

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Phase 3

Recruiting

Conditions: Obesity
Overweight

Interventions: Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2023-10-10

Last Posted Date: 2024-12-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 150

Registration Number: NCT06075667

Locations: 🇨🇦
The Wharton Medical Clinic Clinical Trials Inc, Hamilton, Ontario, Canada
🇺🇸
CenExel iResearch, LLC, Decatur, Georgia, United States
🇺🇸
Solaris Clinical Research, Meridian, Idaho, United States

and more 35 locations

A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-LY3556050

First Posted Date: 2023-09-25

Last Posted Date: 2024-01-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 7

Registration Number: NCT06052462

Locations: 🇺🇸
LabCorp CRU, Inc., Madison, Wisconsin, United States

A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-LY3871801

First Posted Date: 2023-09-21

Last Posted Date: 2024-01-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 8

Registration Number: NCT06049108

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Phase 3

Active, not recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Orforglipron
Drug: Semaglutide

First Posted Date: 2023-09-21

Last Posted Date: 2024-10-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1576

Registration Number: NCT06045221

Locations: 🇲🇽
Caimed Investigacion En Salud S.A. de C.V., Mexico City, Distrito Federal, Mexico
🇺🇸
Absolute Clinical Research, Phoenix, Arizona, United States
🇺🇸
San Fernando Valley Health Institute, Canoga Park, California, United States

and more 127 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy